Abcam and Transinsight Collaborate in the Area of Semantic Search Technologies

Abcam, a bioscience company specialising in the supply of antibodies from a web-based catalogue and Transinsight, a specialist in semantic search technologies announced a collaboration in the field of protein information quality control using bioinformatics workflows.

Accurately compiling all the required information around antibody targets is a challenging task, which has created the requirement for an automated intelligent computer-based solution to ensure top-quality information content about proteins. For example, an average human gene name has 6 or 7 synonyms and many more spelling variants. Hand-curated databases do not cover all possible ways of naming and spelling genes and hand-curation is a tedious, error prone and labour-intensive task.

"Until recently there were only limited software tools and scientific workflows available to help us automatically produce high quality data sets surrounding each of Abcam’s thousands of antibody targets. We need these data sets to help our customers find the right products", says Dr. Harter, Senior Business Development Manager at Abcam. Harter continues "We were looking for solutions for supporting our team of experts and were impressed by the advanced technologies of Transinsight. The fact that the company operates the semantic search engine GoPubMed.org and has extensive bioinformatics and protein databases expertise made the decision to work with Transinsight easy."

The award winning technology behind GoPubMed fully automates very difficult analyses normally done by scientists with equal or better performance, predicting the necessary information by sophisticated algorithms. "It is good to see how we can significantly enhance our customers' performance by improving their data quality and thus freeing their staff from an unnecessary burden" says Michael R. Alvers, CEO at Transinsight.

About Abcam
Abcam plc is a producer and distributor of research-grade antibodies and associated products headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japan office located in Tokyo. The Company produces and distributes its own and third party produced antibodies to academic and commercial customers throughout the world with product information and ordering available through the Company’s website, www.abcam.com. Abcam’s vision is to build the largest online catalogue of the best antibodies in the world.

About Transinsight
Transinsight develops knowledge-based semantic solutions in the Life Sciences. Their flagship products www.Go3R.org and www.GoPubMed.com, renowned biomedical search engines, are the first knowledge-based search systems of the next generation for the Life Sciences on the internet. In acknowledgement of the technologies developed by the company, Transinsight has repeatedly been honoured with international awards. The firm works in close collaboration with the Dresden University of Technology. Selected customers are: Unilever, BASF, BfR, StatoilHydro, Wintershall, Abcam and EMBL. For further information on Transinsight on the internet, see www.transinsight.com.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...